Assertio Holdings, Inc.

NASDAQ:ASRT

Drug Manufacturers - Specialty & Generic

Healthcare
$23.50 +0.04%

+$0.01 today

Market cap
$151.86M
Beta
0.53
P/E (TTM)
-4.2
EPS (TTM)
-$5.55
52W Low $8.61High $23.50

Volume 0.27M

Average 0.33M

ASRT Interest Income

Income earned on cash, deposits, and investments held by the company.

Assertio Holdings, Inc.NASDAQ: ASRT

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $469K fell 34.9% year over year, behind the -25.2% change in trailing-twelve-month interest income. Sequentially, it fell 22.6% from the prior quarter.

Context

  • Interest income amounted to 2.2% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -34.9% toward the trailing-twelve-month pace of -25.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$469K-22.6% QoQ
Last fiscal yearDec 2025
$2.67M-17.3% YoY
LTMMar 2026
$2.41M-25.2% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.9%——
1 year-17.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
2.67M USD
Year-over-year change
-17.3%

Interest Income vs competitors

How ASRT compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -25.2% is the 2nd highest of 10, against a peer median of -43.9%.
  • Interest income amounts to 2.4% of revenue for ASRT, versus a peer median of 1.8%.
ASRT Competitors
Interest Income for ASRT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCRXTScan Therapeutics, Inc.LTM Mar 2026$7.18M USD-43.4%+77.0%78.5%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$5.47M USD-43.9%——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$5.38M USD-44.2%+20.4%—
XBITXBiotech Inc.LTM Mar 2026$5.09M USD-41.2%+14.1%—
FBIOFortress Biotech, Inc.LTM Mar 2026$2.57M USD+9.7%+21.1%3.9%
ASRTAssertio Holdings, Inc.LTM Mar 2026$2.41M USD-25.2%—2.4%
LUNGPulmonx CorporationLTM Mar 2026$2.14M USD-52.3%+20.1%2.4%
VXRTVaxart, Inc.LTM Mar 2026$1.71M USD-31.0%+8.6%0.7%
NTRBNutriband Inc.LTM Apr 2026$22.17K USD-90.0%—1.2%
INCRInterCure Ltd.LTM Jun 2025₪0 ILS-100.0%+22.6%0.0%
Peer median (excluding ASRT) —-43.9%+20.4%1.8%

Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue111.01M156.23M152.07M124.96M118.71M
Cost of Revenue15.83M18.75M27.02M39.23M65.39M
Gross Profit95.18M137.49M125.05M85.73M53.33M
Gross Margin85.7%88.0%82.2%68.6%44.9%
Research & Development002.84M3.82M1.69M
Selling, General & Admin56.56M48.1M69.74M76.95M68.86M
Operating Expenses85.76M98.08M368.59M110.21M70.55M
Depreciation & Amortization29.11M33.4M28.23M25.83M30.01M
EBITDA38.78M90.17M53.17M5.15M3.14M
EBITDA Margin34.9%57.7%35.0%4.1%2.6%
Operating Income9.42M39.41M(243.54M)(24.48M)(17.22M)
Operating Margin8.5%25.2%-160.1%-19.6%-14.5%
Interest Income0003.22M2.67M
Interest Expense10.22M7.96M3.38M3.04M3.08M
Other Income / Expenses(9.98M)(8.24M)(10.52M)2.95M(12.72M)
Income Before Tax(553K)31.17M(254.05M)(21.53M)(29.94M)
Pre-Tax Margin-0.5%19.9%-167.1%-17.2%-25.2%
Income Tax Expense728K(78.46M)77.89M52K435K
Net Income(1.28M)109.63M(331.94M)(21.58M)(30.38M)
Net Margin-1.2%70.2%-218.3%-17.3%-25.6%
EPS (Basic)(0.45)34.95(70.05)(3.45)(4.74)
EPS (Diluted)(0.45)30.45(70.05)(3.45)(4.74)
Weighted Avg Shares2.88M3.13M4.74M6.35M6.4M
Weighted Avg Shares (Diluted)2.88M3.64M4.74M6.35M6.4M

Assertio Holdings, Inc.

NASDAQ:ASRT

Intrinsic Alpha fair value

Locked

Current Price

$23.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.